(Q36263215)

13 August 2017

1 reference

title

New kinetic models for the hepatitis C virus (English)

1 reference

13 August 2017

1 reference

1 reference

4

Stefan Zeuzem

1 reference

13 August 2017

1

Alan S Perelson

1 reference

13 August 2017

Eva Herrmann

2

1 reference

PubMed ID

16175615

13 August 2017

Florence Micol

series ordinal

3

1 reference

PubMed ID

16175615

13 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

13 August 2017

1 reference

13 August 2017

42

1 reference

13 August 2017

749-754

1 reference

13 August 2017

4

1 reference

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

13 August 2017

1 reference

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

7 January 2021

Dynamics of alanine aminotransferase during hepatitis C virus treatment

1 reference

7 January 2021

Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b

1 reference

7 January 2021

Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis C patients: a case control study

1 reference

7 January 2021

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

1 reference

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

7 January 2021

Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus

1 reference

7 January 2021

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

1 reference

7 January 2021

Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection

1 reference

7 January 2021

Hepatitis C viral kinetics in difficult to treat patients receiving high dose interferon and ribavirin

1 reference

7 January 2021

Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin

1 reference

7 January 2021

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin

1 reference

7 January 2021

Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1

1 reference

7 January 2021

Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system

1 reference

7 January 2021

Alpha Interferon Inhibits Hepatitis C Virus Replication in Primary Human Hepatocytes Infected In Vitro

1 reference

7 January 2021

Effect of alpha interferon on the hepatitis C virus replicon

1 reference

7 January 2021

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection

1 reference

7 January 2021

Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients

1 reference

7 January 2021

Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis

1 reference

7 January 2021

Hepatitis C virus kinetics during and immediately after liver transplantation.

1 reference

7 January 2021

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

1 reference

7 January 2021

HIV-1 directly kills CD4+ T cells by a Fas-independent mechanism

1 reference

7 January 2021

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection

1 reference

7 January 2021

Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production

1 reference

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

7 January 2021

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

7 January 2021

Antiviral action of ribavirin in chronic hepatitis C.

1 reference

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

1 reference

7 January 2021

Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy

1 reference

7 January 2021

Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system

1 reference

7 January 2021

Ribavirin Induces Error-Prone Replication of GB Virus B in Primary Tamarin Hepatocytes

1 reference

7 January 2021

New therapies on the horizon for hepatitis C: are we close?

1 reference

7 January 2021

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

1 reference

7 January 2021

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

1 reference

7 January 2021

Viral kinetics in hepatitis C.

1 reference

7 January 2021

Viral kinetics and hepatitis C.

1 reference

7 January 2021

Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20882

1 reference

13 August 2017

1 reference

PubMed ID

16175615